

CORRECTION OPEN



Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

Theodora A. Constantin, Anabel Varela-Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Ellen Olden, Lucy Penfold, Simon Ang, Alice Ormrod, Damien A. Leach, Chun-Fui Lai, Edward K. Ainscow, Ash K. Bahl, David Carling, Matthew J. Fuchter , Simak Ali and Charlotte L. Bevan


© The Author(s) 2024

British Journal of Cancer (2024) 130:892; <https://doi.org/10.1038/s41416-024-02606-w>

Correction to: *British Journal of Cancer* (2023) **128**:2326–2337; <https://doi.org/10.1038/s41416-023-02252-8>, Article published online 19 April 2023

Following the original publication, the authors were notified of an error present in Figure 1, specifically Figure 1bii, where the same image file was used for CDK4 and CDK7.

The corrected version of Figure 1 is produced here.



The authors provided the journal with the original data. The correction does not have any effect on the results or conclusions of the paper.

The original article has been corrected.

appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give

© The Author(s) 2024